scispace - formally typeset
L

Luuk J. Rijzewijk

Researcher at VU University Medical Center

Publications -  33
Citations -  2641

Luuk J. Rijzewijk is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Type 2 diabetes & Pioglitazone. The author has an hindex of 19, co-authored 33 publications receiving 2372 citations. Previous affiliations of Luuk J. Rijzewijk include VU University Amsterdam.

Papers
More filters
Journal ArticleDOI

Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus

TL;DR: Multivariable analysis indicated that myocardial triglyceride content was associated with E/A and E peak deceleration, independently of diabetic state, age, BMI, heart rate, visceral fat, and diastolic blood pressure.
Journal ArticleDOI

Altered Myocardial Substrate Metabolism and Decreased Diastolic Function in Nonischemic Human Diabetic Cardiomyopathy Studies With Cardiac Positron Emission Tomography and Magnetic Resonance Imaging

TL;DR: Evaluating myocardial substrate and high-energy phosphate metabolism in asymptomatic men with well-controlled, uncomplicated type 2 diabetes with verified absence of cardiac ischemia and age-matched control subjects found no direct relation between cardiac diastolic function and parameters of myocardia metabolism.
Journal ArticleDOI

Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus

TL;DR: In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity, but the functional changes were not associated with myocardia substrate and high-energy phosphate metabolism.